---
title: "Understanding the Market | HBM HOLDINGS-B rose over 4% after releasing its first fully human HCAb generation model, accelerating the implementation of new generation therapies"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263415528.md"
description: "HBM HOLDINGS-B's stock price rose by more than 4%, with an increase of 3.29% as of the time of publication, reported at HKD 13.49, with a transaction volume of HKD 52.5408 million. The company launched its first fully human AI HCAb model at the Global R&D Day event held in Shanghai, aimed at accelerating the application of next-generation therapies, including multispecific antibodies and in vivo CAR-T, to promote innovation in biopharmaceutical research and development"
datetime: "2025-10-30T03:08:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263415528.md)
  - [en](https://longbridge.com/en/news/263415528.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263415528.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/263415528.md) | [English](https://longbridge.com/en/news/263415528.md)


# Understanding the Market | HBM HOLDINGS-B rose over 4% after releasing its first fully human HCAb generation model, accelerating the implementation of new generation therapies

According to Zhitong Finance APP, HBM HOLDINGS-B (02142) rose over 4%, and as of the time of writing, it increased by 3.29%, trading at HKD 13.49, with a transaction volume of HKD 52.5408 million.

In terms of news, according to HBM's official WeChat account, on October 28th, the "Zhiyao HBM Huichuang Xingchen" HBM global R&D day event was successfully held in Shanghai, China. At the meeting, HBM officially launched its first fully human AI HCAb model driven by the Hu-mAtrIx™ artificial intelligence platform—the fully human heavy-chain antibody (HCAb) generation and screening model. This model is based on HBM's proprietary Harbour Mice® platform data, integrating a fine-tuned large language model (LLM) for sequence generation, supplemented by high-precision AI classification and drugability prediction models. Unlike traditional screening methods, this platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation.

It is reported that based on this system, the AI HCAb model is expected to accelerate the application of fully human HCAb in the next generation of therapeutic fields—including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs—helping to reshape the landscape of biopharmaceutical R&D. Leveraging AI capabilities and the foundational HCAb technology, HBM is accelerating the implementation of next-generation innovative therapies and uncovering unmet clinical needs through data-driven predictive processes

### 相關股票

- [HBM HOLDINGS-B (02142.HK)](https://longbridge.com/zh-HK/quote/02142.HK.md)

## 相關資訊與研究

- [In pursuit of profit, India Inc slows R&D as innovation takes back seat](https://longbridge.com/zh-HK/news/281098039.md)
- [Styland Subsidiary Commits US$3.4 Million to Alpha Perpetual Income Fund](https://longbridge.com/zh-HK/news/281380835.md)
- [Grace Life-Tech Holdings FY revenue USD 13 million](https://longbridge.com/zh-HK/news/281224946.md)
- [Bharat Wire Ropes Seeks Shareholder Nod via E-Vote for New Statutory Auditor](https://longbridge.com/zh-HK/news/281642977.md)
- [Feiyu Technology Unit Enters Game Business Cooperation Agreement with Tencent Subsidiary](https://longbridge.com/zh-HK/news/281529384.md)